<DOC>
	<DOCNO>NCT00807677</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) TAK-901 subject advance hematological malignancy , assess safety tolerability TAK-901 MTD expand cohort subject order select dose future study .</brief_summary>
	<brief_title>A Phase 1 Dose Escalation Study TAK-901 Subjects With Advanced Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<criteria>Main 1 . The subject one following confirmed diseases refractory relapse establish therapy . Note : A subject one disease intolerant ( define protocol ) establish therapy also allow : 1 . Acute myelogenous leukemia 2 . Acute lymphoblastic leukemia 3 . Chronic myelogenous leukemia ( CML ) ( chronic phase , accelerated phase , blast crisis ) 4 . Chronic lymphocytic leukemia 5 . Multiple myeloma 6 . Waldenstrom 's macroglobulinemia 7 . Intermediate high risk myelodysplastic syndrome 8 . One follow myeloproliferative disorder : Philadelphia chromosomenegative CML ( include blast phase ) . All subtypes myeloid metaplasia myelofibrosis . Advanced polycythemia vera spend phase ( ie , presence anemia ) . 9 . NonHodgkins lymphoma 2 . The interval last prior treatment start study drug administration least 30 day radiotherapy , least 14 day cytotoxic chemotherapy ( 42 day nitrosureas mitomycin C ) , least 5 halflives noncytotoxic agent . The exception hydroxyurea , use prior start study drug Cycle 1 , define protocol . 3 . For subject prior autologous bone marrow peripheral blood stem cell transplantation , interval transplant start study drug administration least 30 day . 4 . For subject prior allogeneic bone marrow peripheral blood stem cell transplantation , interval transplant start study drug administration least 90 day . 5 . If take steroid chronically , subject receive stable steroid dose least 21 day prior start study drug administration , daily steroid dose exceed equivalent 20 mg prednisone . 6 . The subject age 18 year old . 7 . The subject weigh least 45 kg . 8 . The subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . 9 . The subject adequate liver kidney function . 10 . The subject adequate heart function ( left ventricular ejection fraction ≥ 50 % ) . Main Any subject meet follow criterion qualify entry study : 1 . The subject platelet count ( untransfused ) &lt; 50,000/mm3 and/or absolute neutrophil count &lt; 1000/mm3 cause underlying disease infiltrate bone marrow . 2 . The subject evidence active malignancy central nervous system ( CNS ) CNS involvement document within past 90 day . Subjects receive maintenance intrathecal chemotherapy previous CNS involvement current evidence disease allow CNS involvement document 90 day ago . 3 . The subject evidence acute chronic graft versus host disease . 4 . The subject history hypersensitivity allergic reaction attribute compound similar chemical composition TAK901 excipient , Captisol . 5 . The subject pregnant lactating . 6 . The subject myocardial infarction , cerebrovascular accident , transient ischemic attack , clinically significant ventricular arrhythmia , pulmonary embolus within 6 month prior start study drug administration . 7 . The subject 's electrocardiogram demonstrate abnormal QT interval , define protocol . 8 . The subject require dialysis . 9 . The subject systemic anticoagulation therapy . 10 . The subject uncontrolled intercurrent illness define protocol . 11 . The subject know human immunodeficiency virus ( HIV ) infection chronic hepatitis B C. 12 . The subject currently active second malignancy nonmelanoma skin cancer situ carcinoma cervix . A malignancy consider currently active subject receive ongoing therapy remission le 2 year prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Chronic myelogenous leukemia ( CML ) chronic phase , accelerated phase , blast crisis</keyword>
	<keyword>Intermediate high risk myelodysplastic syndrome</keyword>
	<keyword>Philadelphia chromosome-negative CML ( include blast phase )</keyword>
	<keyword>All subtypes myeloid metaplasia myelofibrosis ; advanced polycythemia</keyword>
</DOC>